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Abstract  
Background: Hyponatremia, the commonest electrolyte imbalance encountered in clinical practice, is 
associated with adverse outcomes. Despite this, understanding of the association between hyponatremia and 
stroke mortality outcome is limited. 
Aims: To investigate the association between admission serum sodium and mortality at various time-points after 
stroke. 
Methods: Cases of acute stroke admitted to Norfolk and Norwich University Hospital consecutively from 
January 2003 until June 2013 were included, with mortality outcomes ascertained until the end of December 
2013. Odds ratios (OR) or Hazards ratio (HR) for death were constructed for various time points (within 7 days, 
8-30 days, within 1 year and over full follow-up).  
Results: 8540 participants were included (47.4% male, mean age 77.3 (± 12.0) years). Point prevalence of 
hypernatremia and hyponatremia were 3.3% and 13.8%, respectively. In fully adjusted models controlling for 
age, sex, pre-stroke modified Rankin score, stroke type, Oxford community stroke project class and laboratory 
biochemical and hematological results, the ORs (up to one year)/HRs (for full follow up) for the above time 
points were 1.00, 1.11, 1.03, 1.05 for mild hyponatremia, 1.97, 0.78, 1.11, 1.2 for moderate hyponatremia, 3.31, 
1.57, 2.45, 1.67 for severe hyponatremia and 0.47, 1.23, 1.30, 1.10 for hypernatremia. When stratified by age-
groups, outcomes were poorer in younger hyponatremic patients (aged <75 years).  
Conclusions: Hyponatremia is prevalent in acute stroke admissions and is independently associated with higher 
mortality in patients <75 years.  
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Introduction 
Hyponatremia (serum sodium <135 mmol/L), even when mild, is associated with increased mortality [1-3]. It is 
the commonest electrolyte abnormality encountered in the general population [4] and in patients with stroke [5]. 
Furthermore, low sodium is a recognised risk factor for stroke even at levels normally regarded as 
normonatremic [6]. Moreover, in a study of first ever stroke in patients with chronic kidney disease, 
hyponatremia was an independent predictor of mortality [7]. 
Despite this, only two published studies have specifically investigated the association between admission 
hyponatremia and outcomes after stroke. Hyponatremia was reportedly a predictor of 3-year mortality in acute 
first-ever ischemic stroke independent of other prognostic predictors [8]. More recently, hyponatremia was 
associated with higher mortality in hospital, at 3-months and 12-months follow acute stroke [9]. However, it is 
unclear whether prognosis following acute stroke is affected by the severity of hyponatremia and whether poor 
outcome persists in patients with mild hyponatremia (Na 130-134 mmol/L). Additionally, hypernatremia (Na 
>145 mmol/L) has been reported to be associated with early neurological worsening following stroke [10]. 
Aims 
This study investigated the association between admission serum sodium and mortality at various time-points 
after stroke. Since hyponatremia in older patients is especially common and particularly challenging to manage 
[12], we looked for differences in the impact of dysnatraemias in older versus younger patients, hypothesising 
that the prognostic value of serum sodium would vary with age. 
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Methods 
We used the Norfolk and Norwich Stroke Register that prospectively recorded consecutive patients with a 
diagnosis of acute stroke admitted to Norfolk and Norwich University Hospital since 1996. The hospital hosts 
the only acute stroke unit for a population of approximately 750,000 inhabitants in the city of Norwich and 
surrounding rural areas. Data collection methods of the register have been previously reported [13]. Briefly, data 
were obtained from paper-based and electronic records, reviewed and entered onto the register database by the 
hospital stroke data team. All participants were reviewed and diagnosed by a specialist stroke team. Ethical 
approval was obtained from the Newcastle and Tyneside National Health Service (NHS) Research Ethics 
Committee (12/NE/0170) and the study protocol was approved by the Steering Committee of the Norfolk and 
Norwich Stroke Register. 
For the current study, prospectively collected data included basic demographic characteristics, pre-stroke 
modified Rankin score (mRS) [14], stroke type using the Oxfordshire Community Stroke Project (OCSP) 
classification [15], co-morbidities and results of hematological and biochemistry investigations (hemoglobin, 
white cell count, glucose, urea and sodium). For each patient, the modified pre-stroke mRS, was ascertained 
from nursing and medical records by stroke specialist nurses. Since biochemistry data were electronically 
available after January 2003, we included patients admitted to the unit between January 2003 and June 2013. 
We included all cases of acute ischemic or hemorrhagic stroke, but excluded subarachnoid hemorrhage (SAH) 
and cases of recurrent stroke.  
Admission serum sodium was used to classify participants into mild (Na 130-134 mmol/L), moderate (Na 125-
129 mmol/L) and severe (Na<125mmol/L) hyponatremia, normonatremia (Na 135-145 mmol//L) and 
hypernatremia (Na>145 mmol/L). Follow-up was conducted from admission until December 2013 using the 
hospital administration system and validated using the NHS demographics system. 
The statistical analysis was conducted using Stata 11.2/SE (College Station, TX, USA). One-way rank-based 
ANOVA or chi-squared tests compared baseline characteristics and mortality across sodium groups. A sequence 
of logistic regression models were then fitted to data to estimate the odds ratio of outcome (7 day mortality, 
death within 8-30 days, 1 year mortality) for each sodium group relative to the comparator group. The models 
were adjusted for a) age; b) age, sex, mRS and comorbidities (history of MI, Stroke, TIA, Dementia, Diabetes, 
PVD, heart failure, COPD and asthma); c) factors in (b) and stroke type and OSCP class; d) factors in (c) and 
glucose, urea, white cell count and hemoglobin. For mortality outcome at end of follow up, a Cox proportional 
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hazards model was used along with Kaplan-Meier survival curves, with the same covariates as the model above, 
with censoring at the date of follow-up for those individuals still alive. A stratified analysis for those aged <75 
years and those aged 75 or more was conducted using model (d) and a formal test of interaction was used to test 
the equality of the association with sodium group and outcome between these two age groups.  
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Results 
There were 9835 admissions during the study period. We excluded 99 individuals with no follow-up data, 156 
individuals with SAH, 695 individuals with recurrent stroke and 494 individuals who had no available sodium 
results within one day of admission. Therefore, 8391 cases were included (47.4% male, mean (±SD) age 77.3 (± 
12.0) years).  
The baseline point prevalence of hypernatremia was 3.3%. The prevalences of mild, moderate and severe 
hyponatremia were 10.5%, 2.7% and 0.6%, respectively. A comparison of baseline characteristics and outcomes 
according to natremic group is shown in Table 1. The mortality for the entire cohort of 8391 patients was 12.9% 
at one week, 15.0% at 30 days and 39.1% at one year. Patients with sodium disturbances were older, had higher 
prior disability (depicted by pre-stroke mRS), higher white cell counts and higher prevalence of diabetes. 
Hyponatremia was more common in females whilst the prevalence of dementia was higher in hypernatremic 
patients.  
Both hypo- and hypernatremia were associated with increased mortality at all selected time-points (Table 2 and 
Figure 1). However, the increased odds of death in mild hyponatremia (Na 130-134 mmol/L) and hypernatremia 
(Na >145 mmol/L) did not reach statistical significance and were similar to the normonatremic group after 
adjustments. 
The fully-adjusted sub-group analysis by age categories (Table 3) showed that hyponatremia in younger 
patients, especially when severe, was independently associated with higher mortality at all time-points. 
Intriguingly, younger patients with hyponatremia continued to have increased risk of death beyond one year 
after their stroke, even when hyponatremia was mild. In older patients, difference in odds of death by sodium 
level did not reach statistical significance at most time-points. 
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Discussion 
Our study is the largest to date to investigate the association between admission sodium levels and mortality 
after stroke. It confirms findings from smaller studies reporting that hyponatremia is an independent predictor of 
poor outcome after stroke both in the short [9] and long term [8]. Additionally, our findings show for the first 
time that this association is driven mostly by increased risk of death with hyponatremia in younger stroke 
patients. Also, the increased mortality with hypernatremia disappears after adjustment for potential confounders 
such as urea, a marker of hydration [16]. 
The 13.8% prevalence of hyponatremia on admission in our sample of stroke patients was similar to that 
observed in comparable literature by Rodrigues et al. (16%) [9] and Huang et al. (12%) [8], but lower than that 
seen in acute geriatric medicine wards (18%) [17], where patients are older. However, mortality in our study 
was much higher than in the study by Huang, where mortality was just 8.8% at 3 years follow-up [8]. We also 
observed a higher mortality than the 29% seen at 1 year in the registry study by Rodrigues [9]. These differences 
are possibly due to our older, unselected sample population. It is unclear why our population is older than other 
published studies but probably reflects that frail older people in our study registry were not excluded from 
access to an acute stroke unit, as per best practice guidelines [18]. Also, our inclusion of both hemorrhagic and 
ischemic stroke, rather than just ischemic stroke, may have contributed to these differences. 
Strikingly, younger patients with hyponatremia are at a higher risk of death. We initially hypothesised that older 
people would be at highest risk due to frailty and increased susceptibility to other adverse effects of 
hyponatremia, including confusion [12], falls [19] and fractures [20]. There are a number of possible 
explanations for this unexpected observation. Acute hyponatremia is well known to cause cerebral oedema [21] 
but older individuals may be more likely to survive because age-related cerebral atrophy will protect against 
fatal coning due to raised intracranial pressure. Also, the increased susceptibility to dyshomeostasis (and 
consequent hyponatremia) in older people [22] suggests that they may become hyponatremic due to less severe 
and/or more easily remediable causes than younger individuals. Such cases of hyponatremia, in older people, are 
predominantly mild and chronic (i.e. developing >48 hours) [11]. In this study we did not account for rate of 
development of hyponatremia which is a more important prognostic predictor than absolute serum sodium 
measurements [23]. Therefore, it is plausible that acute hyponatremia may be more common in younger people 
and that rate of development of hyponatremia may account for the worse prognosis in younger people with 
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stroke. Since hyponatremia in younger patients continued to predict mortality beyond the short-term, it seems 
unlikely that cerebral oedema alone could continue to explain the association with increased mortality. 
There were important differences at baseline (Table 1) between the various natremic groups, many of which 
may partly explain the unadjusted association between dysnatremias and death. In particular, older, frailer 
individuals with diabetes were more prone to dysnatremia, and those with hypernatremia were more likely to 
have dementia and present with total anterior circulation stroke. Hyponatremia was more common in women, in 
keeping with other observational studies [24]. 
Dysnatremia was associated with increased odds of death at all time-points, albeit with attenuation in magnitude 
of association after adjustment for multiple potential confounders. Surprisingly, the exception was that the odds 
of death with hypernatremia were significantly lower in the fully adjusted model. This suggests it is dehydration 
rather than hypernatremia that accounts for the excess mortality in the hypernatremic group. This is important as 
dehydration should be easily remediable, although stroke and hypernatremia may be terminal events for some 
individuals, and a palliative approach may have been appropriately instituted. The increased odds of death with 
mild hyponatremia were modest and did not reach statistical significance, but this may reflect a lack of power 
and would be unwise to dismiss since hyponatremia may also be very treatable. Previous groups have found that 
both mild hyponatremia and serum sodium levels within the lower range of normonatremia (serum sodium<137) 
are associated with increased mortality in hospitalised adult patients [25, 26]. 
Since hyponatremia is often chronic and notoriously challenging to manage [12], it is possible that many 
patients in this cohort remained chronically hyponatremic, as observed in non-stroke populations [27]. However, 
because we only utilised admission serum sodium measurements, this could not be assessed. Chronic 
hyponatremia in the general population is associated with increased mortality, even when mild [1], potentially 
explaining the longer term association with increased mortality in younger patients who have longer life 
expectancy compared to their older counterparts. Due to the limited life expectancy of our older co-morbid 
participants, it is possible that our analysis lacked power to detect an independent association with mortality at 
longer-term follow-up in the older patients due to the modest numbers of survivors and because moderate and 
severe hyponatremic cases were uncommon. There are no studies that carefully examine the causes of 
hyponatremia after stroke. Unfortunately, we do not have data on aetiology of hyponatremia encountered in this 
study either, which is a limitation of this report. 
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Our study has some other limitations that should be considered. We used only baseline sodium measurements to 
highlight the potential impact of dysnatremia on stroke outcome. Also, in any observational study it is possible 
that there are unmeasured confounders. However, we robustly adjusted for patient related factors 
(demographics/co-morbidities/prestroke disability), stroke related factors (type), and acute haematological and 
biochemical parameters. We did not measure the severity of stroke other than by OCSP class. Despite these 
limitations, this report makes an important contribution to understanding of dysnatremia and post-stroke 
mortality. We studied a large and unselected study population and availability of outcome data was complete. 
Whilst the association between hyponatraemia and mortality cannot prove causation, the independent 
association observed in this prospective study raises an important question. Would timely and appropriate 
management of hyponatraemia improve stroke mortality? This requires further study in a randomised controlled 
trial as it remains possible hyponatraemia is a marker of severity of underlying dyshomeostasis or disease. Our 
study does not provide information on the causes of hyponatremia, or what efforts were made to correct it. We 
therefore do not know how often hyponatremia was resistant to treatment. 
In summary, our study provides the strongest and largest evidence to date on the association between admission 
dysnatraemias and mortality after stroke. This is clinically significant as it raises the possibility that better 
prevention and management of hypo- and hypernatremia may improve outcomes after stroke. Future studies 
should investigate the causes of hyponatremia after stroke, and whether therapeutic strategies to achieve 
normonatremia may lead to improved outcomes.  
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Tables 
Table 1: Sample characteristics categorised by sodium measurement (mmol/L) 
Variable 
 
Sodium<125 
 
Sodium 125-129 Sodium 130-134 
 
Sodium 135-144 
 
Sodium≥145 
 
P value 
Number (N) 
 
57 
 
230 
 
884 
 
6945 
 
275 
 
 
Age 79.3 (9.72) 80.32 (8.92) 79.92 (10.35) 76.8 (12.13) 77.63 (13.31) <0.001 
 
Male sex 19 (33.3) 77 (33.5) 328 (37.1) 3413 (49.1) 138 (50.2) 
 
<0.001 
 
Pre-stroke mRs* 
      
<0.001 
0 23 (46.9) 100 (48.3) 425 (53.3) 4286 (66.3) 119 (49.4)  
1 8 (16.3) 35 (16.9) 108 (13.5) 680 (10.5) 19 (7.9)  
2 5 (10.2) 20 (9.7) 84 (10.5) 501 (7.7) 16 (6.6)  
3 9 (18.4) 28 (13.5) 104 (13) 564 (8.7) 43 (17.8)  
4 2 (4.1) 16 (7.7) 48 (6) 313 (4.8) 23 (9.5)  
5 2 (4.1) 8 (3.9) 29 (3.6) 121 (1.9) 21 (8.7)  
 
Previous stroke  17 (29.8) 55 (23.9) 183 (20.7) 1319 (19) 69 (25.1) 
 
0.007 
 
Previous TIA 1 (1.8) 12 (5.2) 36 (4.1) 286 (4.1) 8 (2.9) 
 
0.639 
 
Stroke type 
      
0.003 
 Bleed 8 (14) 44 (19.1) 140 (15.8) 916 (13.2) 24 (8.7)  
 Infarct 49 (86) 186 (80.9) 744 (84.2) 6029 (86.8) 251 (91.3)  
 
Bamford Classification 
     <0.001 
LACS** 15 (26.3) 43 (18.8) 171 (19.5) 1597 (23.1) 48 (17.5)  
PACS*** 14 (24.6) 74 (32.3) 278 (31.7) 2253 (32.6) 70 (25.5)  
POCS**** 12 (21.1) 43 (18.8) 151 (17.2) 1155 (16.7) 35 (12.8)  
TACS***** 10 (17.5) 42 (18.3) 196 (22.3) 1434 (20.8) 74 (27)  
UNK****** 6 (10.5) 27 (11.8) 81 (9.2) 466 (6.7) 47 (17.2)  
 
Follow-up period/ period till death 
725.81 (1016.42) 
 
736 (933.23) 
 
763.15 (957.28) 
 1029.05 (1100.21) 
895.94 
(1181.48) 
 
<0.001 
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Glucose 7.75 (4.59) 7.78 (4.52) 8.18 (4.56) 7.2 (2.86) 7.58 (3.96) 
 
0.001 
 
Urea 7.31 (6.19) 7.29 (5.55) 7.8 (5.01) 7.69 (4.12) 13.95 (11.02) 
 
<0.001 
 
Sodium 120.18 (4.34) 127.55 (1.35) 132.53 (1.37) 139.37 (2.32) 147.69 (4.67) 
 
<0.001 
 
HB 12.8 (2.12) 12.8 (1.81) 12.89 (2) 13.58 (1.9) 13.6 (2.35) 
 
<0.001 
 
WBC 10.67 (5.26) 10.94 (5.38) 10.77 (7.27) 9.98 (8.85) 11.73 (6) 
 
<0.001 
 
Asthma 3(5.3) 21(9.1) 81(9.2) 470(6.8) 23(8.4) 
 
0.056 
 
COPD 8(14) 14(6.1) 60(6.8) 393(5.7) 17(6.2) 
 
0.065 
 
CHF 8(14) 21(9.1) 105(11.9) 706(10.2) 39(14.2) 
 
0.099 
 
Diabetes 11(19.3) 34(14.8) 131(14.8) 762(11) 36(13.1) 
 
0.001 
 
Dementia 1(1.8) 15(6.5) 39(4.4) 249(3.6) 29(10.5) 
 
<0.001 
 
PVD 2(3.5) 3(1.3) 35(4) 242(3.5) 9(3.3) 
 
0.421 
 
MI 4(7) 10(4.3) 55(6.2) 394(5.7) 21(7.6) 
 
0.520 
 
Dead within 7 days 
 
12(21.1) 
 
47(20.4) 
 
133(15) 
 
845(12.2) 
 
62(22.5) 
 
<0.001 
 
Death 8-30 days 7(12.3) 26(11.3) 105(11.9) 618(8.9) 44(16) 
 
<0.001 
 
Death within 1 year
* 
33(60) 115(50.4) 401(47.2) 2491(37.4) 148(54.8) 
 
<0.001 
 
Death 40(70.2) 156(67.8) 553(62.6) 3736(53.8) 206(74.9) 
 
<0.001 
* mRs= modified Rankin score (0=no symptoms, 1=no significant disability, 2=slight disability, 3=moderate disability, 4=moderately-severe disability, 5= severe disability, 6=dead) 
**LAC = lacunar stroke     ***PACS = partial anterior circulation stroke      ****POCS = Posterior circulation stroke       ***** TACS = Total anterior stroke        ****** UNK = Unknown 
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Table 2: Odds Ratios (OR) for death at various time-points and Cox proportional hazards ratio (HR) for death using normonatremia as the reference category 
Variable 
 
Sodium<125 Sodium 125-129 
 
Sodium 130-134 
 
Sodium 135-144 
 
Sodium≥145 
 
7 day mortality (OR)     
Model A* 1.83 (0.96-3.49) 1.72 (1.24-2.39) 1.19 (0.97-1.45) 1 2.06 (1.54-2.77) 
Model B** 2.19 (1.10-4.36) 1.98 (1.39-2.82) 1.17 (0.93-1.45) 1 1.97 (1.42-2.73) 
Model C*** 2.84 (1.29-6.22) 2.03 (1.35-3.08) 1.01 (0.79-1.30) 1 1.51 (1.04-2.19) 
Model D**** 3.31 (1.27-8.62) 1.97 (1.15-3.38) 1.00 (0.72-1.38) 1 0.47 (0.25-0.88) 
 
Death between 8-30 days (OR)     
Model A* 1.41 (0.62-3.22) 1.24 (0.80-1.90) 1.21 (0.97-1.52) 1 2.28 (1.60-3.26) 
Model B** 1.43 (0.58-3.55) 0.94 (0.56-1.57) 1.27 (0.99-1.61) 1 1.93 (1.29-2.88) 
Model C*** 1.66 (0.64-4.34) 1.04 (0.61-1.78) 1.24 (0.96-1.60) 1 1.73 (1.12-2.67) 
Model D**** 1.57 (0.47-5.32) 0.78 (0.37-1.63) 1.11 (0.79-1.57) 1 1.23 (0.69-2.21) 
 
Death within 1 year (OR)     
Model A* 2.43 (1.38-4.27) 1.48 (1.12-1.95) 1.30 (1.12-1.51) 1 2.08 (1.60-2.71) 
Model B** 2.69 (1.44-5.04) 1.36 (1.01-1.83) 1.27 (1.08-1.49) 1 1.80 (1.34-2.41) 
Model C*** 3.23 (1.66-6.30) 1.37 (1.00-1.89) 1.23 (1.03-1.48) 1 1.61 (1.16-2.23) 
Model D**** 2.45 (1.08-5.55) 1.11 (0.73-1.68) 1.03 (0.82-1.31) 1 1.30 (0.82-2.08) 
 
Death (HR)      
Model A* 1.39 (1.02-1.91) 1.30 (1.11-1.53) 1.16 (1.06-1.27) 1 1.68 (1.45-1.94) 
Model B** 1.46 (1.05-2.04) 1.26 (1.06-1.50) 1.14 (1.03-1.26) 1 1.55 (1.33-1.81) 
Model C*** 1.43 (1.03-2.00) 1.29 (1.08-1.53) 1.08 (0.98-1.19) 1 1.42 (1.22-1.66) 
Model D**** 1.67 (1.13-2.47) 1.20 (0.96-1.51) 1.05 (0.92-1.19) 1 1.10 (0.88-1.36) 
*model a- adjusted for age      **model b- adjusted for age, sex, co-morbidities and pre-stroke mRs      ***model c- adjustment as for model b plus stroke type and OCSP classification 
****model d- adjustment as for model c plus adjustment for haematological and biochemistry data 
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Table 3: Fully-adjusted sub-group analysis by age categories 
Age group Sodium<125 Sodium 125-129 Sodium 130-134 Sodium 135-144 Sodium ≥145 p-value  
7 day mortality     0.3279 
<75 years 13.9 (2.41-80.5) 1.89 (0.57-6.30) 1.41 (0.71-2.80) 1 0.53 (0.16-1.81)  
≥75 years 1.72 (0.49-5.96) 2.00 (1.09-3.66) 0.93 (0.64-1.36) 1 0.46 (0.22-0.95)  
 
Death between 8-30 days 
    0.1662 
<75 years 8.92 (0.67-119) 1.22 (0.14-10.8) 2.47 (1.04-5.85) 1 0.40 (0.046-3.54)  
≥75 years 1.09 (0.27-4.43) 0.74 (0.34-1.63) 0.97 (0.67-1.41) 1 1.40 (0.76-2.59)  
 
Death within 1 year 
    0.0809 
<75 years 8.21 (1.40-48.1) 0.90 (0.32-2.59) 1.56 (0.94-2.59) 1 0.92 (0.38-2.22)  
≥75 years 1.44 (0.54-3.80) 1.17 (0.75-1.82) 0.92 (0.71-1.20) 1 1.29 (0.74-2.23)  
 
Death 
    0.0011 
<75 years 4.21 (1.99-8.88) 0.98 (0.55-1.76) 1.45 (1.07-1.95) 1 1.03 (0.66-1.61)  
≥75 years 1.21 (0.76-1.92) 1.22 (0.96-1.56) 0.96 (0.83-1.11) 1 1.05 (0.82-1.34)  
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Figure 1: Kaplan Meier Survival Curves 
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